Licensing status

Publication and contact information

Assays & screens

Measurement of b-amyloid (Ab) oligomers in cerebrospinal fluid (CSF) to diagnose and monitor the progression of Alzheimer's disease (AD)

An assay that measures Ab oligomers levels in CSF could help diagnose AD and monitor disease progression in patients. An ELISA using an anti-Ab oligomer mAb detected Ab oligomers in CSF at levels as low as 0.09 picograms/mL. In CSF from patients with AD, Ab oligomer levels were higher than those in CSF from healthy controls and patients with Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) or schizophrenia. In patients with AD, Ab oligomer levels correlated with disease severity as measured by mini-mental state examination (MMSE) scores. Next steps could include testing diagnostic applications of the assay in a larger cohort of patients with AD.

SciBX 7(10); doi:10.1038/scibx.2014.293
Published online March 13, 2014

Patent and licensing status unavailable

Savage, M.J. et al. J. Neurosci.; published online Feb. 19, 2014;
Contact: Mary J. Savage, Merck & Co. Inc., West Point, Pa.